Clinical Trial

Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025

BERKELEY, Calif. and MAINZ, Germany, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”),…

1 year ago

Aligos Therapeutics Appoints David Perry as Vice President of Business Development

SOUTH SAN FRANCISCO, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company…

1 year ago

Barinthus Bio Completes Enrollment for Phase 2b HBV003 Clinical Trial in Chronic Hepatitis B and Phase 1 PCA001 Clinical Trial in Prostate Cancer

Investigational immunotherapy, VTP-300, is being evaluated as part of a potential functional cure regimen for chronic Hepatitis B.Interim data update…

1 year ago

Spago Nanomedical in New Phase with Full Focus on the Tumorad Program

LUND, SWEDEN / ACCESSWIRE / October 1, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) The Board of Directors of Spago Nanomedical AB…

1 year ago

AlzeCure’s Abstract on ACD856’s Anti-inflammatory Effects to be Presented at a Leading Alzheimer’s Conference

STOCKHOLM, SWEDEN / ACCESSWIRE / October 1, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical…

1 year ago

ATPC and FORMEDIC Technologies Announce Strategic Collaboration to Launch LEGA, a Revolutionary Respiratory Care Device

Innovative Collaboration Brings Advanced Respiratory Solutions to a Global Market KUALA LUMPUR, MALAYSIA / ACCESSWIRE / September 30, 2024 /…

1 year ago

Introducing Perceptive: A New Name for the Global Leader in Discovery, eClinical, and Imaging Services and Solutions

Calyx and Invicro rebrand, usher in a new era of leadership and support to the biopharmaceutical community NOTTINGHAM, England, Sept. 30,…

1 year ago

Biophytis Publishes First-Half Financial Results and Provides an Update on its Business Activities

PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / September 30, 2024 / Biophytis SA (Euronext Growth Paris:ALBPS) ("Biophytis" or the…

1 year ago

National Organization for Rare Disorders (NORD) Announces $85,000 in Grant Funding for Amyloidosis and Levy-Yeboa Syndrome

QUINCY, Mass., Sept. 30, 2024 /PRNewswire/ -- Today, the National Organization for Rare Disorders (NORD®) announced two new requests for proposal…

1 year ago